Skip to main content

Advertisement

SpringerLink
Log in

The Prognostic Significance of the BIN1 and CCND2 Gene in Adult Patients with Acute Myeloid Leukemia

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Objective

To investigate the expression and clinical significance of Bridging INtegrator 1 (BIN1) and cyclin D2 (CCND2) in newly diagnosed cytogenetically heterogenous adult acute myeloid leukemia patients. Methods Real-time quantitative PCR (RQ-PCR) was used to detect the expression of BIN1 and CCND2 genes in 49 newly diagnosed adult patients with AML, and their clinical significance was analyzed. Results BIN1 and CCND2 genes are highly expressed in patients with AML, which suggest their potential as molecular markers. A statistical significant correlation was found between BIN1 expression with bone marrow blasts (P = 0.012), CD34 expression (P = 0.026), NLR (P = 0.019) and Karyotype risk (P = 0.005). There was a statistically significant correlation between CCND2 and age (P = 0.001), NLR (P = 0.046) Karyotype risk (P = 0.033). The expression level of BIN1 was related to early treatment response (CR or not) (P = 0.043). CCND2 expression was significantly correlated with overall survival (P = 0.013), but not with CR (P = 0.731). Conclusion BIN1 and CCND2 genes are highly expressed in patients with AML, suggesting the potential of these two genes as molecular markers. Moreover, high levels of CCND2 are associated with better prognosis, suggesting the possibility of these two genes as prognostic markers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Siegel RL, Miller KD (2019) Jemal A (2019) Cancer statistics. CA Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.21551

    Article  PubMed  Google Scholar 

  2. Green CL, Koo KK, Hills RK et al (2010) Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 28(16):2739–2747. https://doi.org/10.1200/jco.2009.26.2501

    Article  CAS  PubMed  Google Scholar 

  3. Pyndiah S, Tanida S, Ahmed KM et al (2011) c-MYC suppresses BIN1 to release poly (ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal 4(166):ra19. https://doi.org/10.1126/scisignal.2001556

    Article  CAS  PubMed  Google Scholar 

  4. Elliott K, Ge K, Du W et al (2000) The c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program. Oncogene 19(41):4669–4684. https://doi.org/10.1038/sj.onc.1203681

    Article  CAS  PubMed  Google Scholar 

  5. Muller AJ, Baker JF, DuHadaway JB et al (2003) Targeted disruption of the murine Bin1/Amphiphysin II gene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol 23(12):4295–4306. https://doi.org/10.1128/MCB.23.12.4295-4306.2003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Esmailzadeh S, Huang Y, Su MW et al (2015) BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma. Leukemia 29(6):1402–1413. https://doi.org/10.1038/leu.2015.9

    Article  CAS  PubMed  Google Scholar 

  7. Wang X, Wang J, Jia Y et al (2017) Methylation decreases the Bin1 tumor suppressor in ESCC and restoration by decitabine inhibits the epithelial mesenchymal transition. Oncotarget 8(12):19661–19673. https://doi.org/10.18632/oncotarget.14914

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jia Y, Wang H, Wang Y et al (2015) Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer 137(5):1095–1106. https://doi.org/10.1002/ijc.29481

    Article  CAS  PubMed  Google Scholar 

  9. Wang J, Jia Y, Zhao S et al (2017) BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer. Oncogene 36(45):6235–6243. https://doi.org/10.1038/onc.2017.217

    Article  CAS  PubMed  Google Scholar 

  10. Ge Y, Schuster MB, Pundhir S et al (2019) The splicing factor RBM25 controls MYC activity in acute myeloid leukemia. Nat Commun 10(1):172. https://doi.org/10.1038/s41467-018-08076-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhu C, Shao P, Bao M et al (2014) miR-154 inhibits prostate cancer cell proliferation by targeting CCND2. Urol Oncol 32(1):31.e9-31.e16. https://doi.org/10.1016/j.urolonc.2012.11.013

    Article  CAS  Google Scholar 

  12. Zhou J, Tian Y, Li J et al (2013) miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun 433(2):207–212. https://doi.org/10.1016/j.bbrc.2013.02.084

    Article  CAS  PubMed  Google Scholar 

  13. Du X, Lin LI, Zhang L et al (2015) microRNA-195 inhibits the proliferation, migration and invasion of cervical cancer cells via the inhibition of CCND2 and MYB expression. Oncol Lett 10(4):2639–2643. https://doi.org/10.3892/ol.2015.3541

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Faber ZJ, Chen X, Gedman AL et al (2016) The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet 48(12):1551–1556. https://doi.org/10.1038/ng.3709

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Eisfeld AK, Kohlschmidt J, Schwind S et al (2017) Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 31(6):1278–1285. https://doi.org/10.1038/leu.2016.332

    Article  CAS  PubMed  Google Scholar 

  16. Martinez-Soria N, McKenzie L, Draper J et al (2018) The oncogenic transcription factor RUNX1/ETO corrupts cell cycle regulation to drive leukemic transformation. Cancer Cell 34(4):626-642.e8. https://doi.org/10.1016/j.ccell.2018.08.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Liu W, Yi JM, Liu Y et al (2021) CDK6 Is a potential prognostic biomarker in acute myeloid leukemia. Front Genet 11:600227. https://doi.org/10.3389/fgene.2020.600227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Raeisi Shahraki H, Bemani P, Jalali M (2017) Classification of bladder cancer patients via penalized linear discriminant analysis. Asian Pac J Cancer Prev 18(5):1453–1457. https://doi.org/10.22034/APJCP.2017.18.5.1453

    Article  PubMed  Google Scholar 

  19. Vincenzi B, Stacchiotti S, Collini P et al (2017) Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. Br J Cancer 117(3):340–346. https://doi.org/10.1038/bjc.2017.187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Pan K, Liang XT, Zhang HK et al (2012) Characterization of bridging integrator 1 (BIN1) as a potential tumor suppressor and prognostic marker in hepatocellular carcinoma. Mol Med 18(1):507–518. https://doi.org/10.2119/molmed.2011.00319

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tanida S, Mizoshita T, Ozeki K et al (2012) Mechanisms of cisplatin-induced apoptosis and of cisplatin sensitivity: potential of BIN1 to act as a potent predictor of cisplatin sensitivity in gastric cancer treatment. Int J Surg Oncol 2012:862879. https://doi.org/10.1155/2012/862879

    Article  PubMed  PubMed Central  Google Scholar 

  22. Sun CC, Zhang L, Li G et al (2017) The lncRNA PDIA3P interacts with miR-185-5p to modulate oral squamous cell carcinoma progression by targeting cyclin D2. Mol Ther Nucleic Acids 9:100–110. https://doi.org/10.1016/j.omtn.2017.08.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wang Y, Xue J, Kuang H et al (2017) microRNA-1297 inhibits the growth and metastasis of colorectal cancer by suppressing cyclin D2 expression. DNA Cell Biol 36(11):991–999. https://doi.org/10.1089/dna.2017.3829

    Article  CAS  PubMed  Google Scholar 

  24. Takano Y, Kato Y, van Diest PJ et al (2000) Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 156(2):585–594. https://doi.org/10.1016/S0002-9440(10)64763-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Sicinski P, Donaher JL, Geng Y et al (1996) Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384(6608):470–474. https://doi.org/10.1038/384470a0

    Article  CAS  PubMed  Google Scholar 

  26. Chen BB, Glasser JR, Coon TA et al (2012) F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. Blood 119(13):3132–3141. https://doi.org/10.1182/blood-2011-06-358911

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Swart LE, Heidenreich O (2021) The RUNX1/RUNX1T1 network: translating insights into therapeutic options. Exp Hematol 94:1–10. https://doi.org/10.1016/j.exphem.2020.11.005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282. https://doi.org/10.1182/blood-2003-05-1545

    Article  CAS  PubMed  Google Scholar 

  29. Mermelshtein A, Gerson A, Walfisch S et al (2005) Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer 93(3):338–345. https://doi.org/10.1038/sj.bjc.6602709

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. He X, Chen SY, Yang Z et al (2018) miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 (CCND2). J Exp Clin Cancer Res 37(1):230. https://doi.org/10.1186/s13046-018-0882-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ko E, Kim Y, Park SE et al (2012) Reduced expression of cyclin D2 is associated with poor recurrence-free survival independent of cyclin D1 in stage III non-small cell lung cancer. Lung Cancer 77(2):401–406. https://doi.org/10.1016/j.lungcan.2012.03.027

    Article  PubMed  Google Scholar 

  32. Sarkar R, Hunter IA, Rajaganeshan R et al (2010) Expression of cyclin D2 is an independent predictor of the development of hepatic metastasis in colorectal cancer. Colorectal Dis 12(4):316–323. https://doi.org/10.1111/j.1463-1318.2009.01829.x

    Article  CAS  PubMed  Google Scholar 

  33. Matsubayashi H, Sato N, Fukushima N et al (2003) Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 9(4):1446–1452

    CAS  PubMed  Google Scholar 

  34. Evron E, Umbricht CB, Korz D et al (2001) Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 61(6):2782–2787

    CAS  PubMed  Google Scholar 

  35. Ahmadzada T, Lee K, Clarke C et al (2019) High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. Lung Cancer 130:35–41. https://doi.org/10.1016/j.lungcan.2019.02.005

    Article  PubMed  Google Scholar 

  36. Fang X, Chen C, Xia F et al (2016) CD274 promotes cell cycle entry of leukemia-initiating cells through JNK/Cyclin D2 signaling. J Hematol Oncol 9(1):124. https://doi.org/10.1186/s13045-016-0350-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by Sichuan Department of Science and Technology (Grant No. 20YYJC0940) and Lu zhou people's government- Southwest Medical University joint Project (Grant No. 2017LZXNYD-Z06)

Author information

Author notes

  1. Xinwen Zhang and Hao Xiong have contributed equally to this work.

Authors and Affiliations

  1. Stem Cell Laboratory and Department of Hematology, Affiliated Hospital of Southwest Medical University, Sichuan Province, Luzhou City, China

    Xinwen Zhang, Hao Xiong, Jialin Duan, Xiaomin Chen, Yang Liu & Chunlan Huang

Authors
  1. Xinwen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hao Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jialin Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaomin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chunlan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

For every author, his or her contribution to the manuscript needs to be provided using the following categories: CONCEPTION: Chunlan Huang, Xinwen Zhang, Hao Xiong, INTERPRETATION OR ANALYSIS OF DATA: Xinwen Zhang, Hao Xiong, Xiaomin Chen, Yang Liu, Jialin Duan. PREPARATION OF THE MANUSCRIPT: Xinwen Zhang, Hao Xiong. REVISION FOR IMPORTANT INTELLECTUAL CONTENT: Xinwen Zhang, Hao Xiong, Xiaomin Chen, Yang Liu, Jialin Duan. SUPERVISION: Chunlan Huang.

Corresponding author

Correspondence to Chunlan Huang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interests.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

Human and Animal Participants

This study involves blood and bone marrow aspirates from AML patients. Ethical approval was obtained from institutional ethics committee (AF-V4-22.0) to conduct the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Xiong, H., Duan, J. et al. The Prognostic Significance of the BIN1 and CCND2 Gene in Adult Patients with Acute Myeloid Leukemia. Indian J Hematol Blood Transfus 38, 481–491 (2022). https://doi.org/10.1007/s12288-021-01479-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-021-01479-w

Keywords

Search

Navigation